Last reviewed · How we verify
Neuro-Cells
At a glance
| Generic name | Neuro-Cells |
|---|---|
| Sponsor | Neuroplast |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Exosomes Effect on Visual Function in CVI
- A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) (PHASE1, PHASE2)
- Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy (PHASE1, PHASE2)
- Senicapoc and Perampanel for Newly Diagnosed Glioblastoma (EARLY_PHASE1)
- A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain (PHASE2)
- An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (PHASE2)
- Sapu003 in Advanced mTOR-sensitive Solid Tumors (PHASE1)
- Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neuro-Cells CI brief — competitive landscape report
- Neuro-Cells updates RSS · CI watch RSS
- Neuroplast portfolio CI